RECOMBINANT ADENOVIRUS EXPRESSING ALPHA-A-CRYSTALLIN GENE AND GENE THERAPY FOR RETINALVASCULAR DISEASE USING THE SAME

The present invention relates to a recombinant adenovirus expressing an alphaA-crystallin gene, and gene therapy for retinal vascular disease using the recombinant adenovirus. Gene therapy using the recombinant adenovirus comprising an alphaA-crystallin gene of the present invention increases the ex...

Full description

Saved in:
Bibliographic Details
Main Authors KIM YOUNG HEE, PARK SO YUN, CHO GYEONG JAE, PARK JAE YONG, HWANG EUN MI, CHOI WAN SUNG
Format Patent
LanguageEnglish
Published 16.01.2014
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a recombinant adenovirus expressing an alphaA-crystallin gene, and gene therapy for retinal vascular disease using the recombinant adenovirus. Gene therapy using the recombinant adenovirus comprising an alphaA-crystallin gene of the present invention increases the expression level of the alphaA-crystallin gene in the damaged retinal pericytes to suppress pericyte loss and death, retinal vascular leakage, and leukocyte adhesion surrounding retinal vessels, thereby protecting the pericytes. Therefore, it can be used for the prevention and treatment of various retinal vascular diseases including diabetic retinopathy.
Bibliography:Application Number: US201213980876